SV investment has resulted in the approval of 24 novel therapeutics
SV News
14 November 2024Portfolio NewsTRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
31 October 2024SV NewsSV is hiring: Executive Assistant
8 October 2024Portfolio NewsMestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases
3 October 2024Portfolio NewsEnara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024Portfolio NewsLoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease
24 September 2024Portfolio NewsQuell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
19 September 2024Portfolio NewsPrilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer- 3 September 2024Portfolio NewsPrilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
- 28 August 2024Portfolio NewsMestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300
29 July 2024Portfolio NewsBioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide
12 July 2024SV NewsUK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce- 10 July 2024Portfolio NewsQuell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors
